Effects of the Sequence of Empiric Beta-Lactam and Vancomycin Administration on Clinical Outcomes in Patients with Bloodstream Infection: A Systematic Review

<b>Background/Objectives</b>: Beta-lactam antibiotics (BLAs) and vancomycin have remained the cornerstones of therapy for serious bacterial infections, especially bloodstream infections (BSIs). The clinical impact of administering BLAs before vancomycin on outcomes remains unclear and poorly synthesized. Therefore, this systematic review aims to synthesize the available evidence on the impact of the relative timing of BLA administration to vancomycin initiation on important clinical outcomes in patients with BSIs. <b>Methods</b>: A comprehensive search was performed to retrieve clinical studies that evaluated the impact of the sequence of BLA and vancomycin administration on clinical outcomes. Beta-lactam-first group (BLF) included patients who received a BLA before vancomycin, while vancomycin-first group (VF) included patients who received vancomycin prior to BLAs. The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. <b>Results</b>: A total of three retrospective observational studies were included, with a sample size of 29,005 patients, with 24,356 patients in the BLF and 4649 patients in the VF. One study reported that prioritizing BLAs over vancomycin resulted in a 52% reduction in 7-day mortality (adjusted OR, 0.48; 95% CI, 0.33-0.69) and a 55% reduction in 48 h mortality (adjusted OR: 0.45; 95% Cl, 0.24-0.83). Similarly, another study found the BLF strategy was associated with a modest reduction in in-hospital mortality (adjusted OR: 0.89; 95% CI: 0.80-0.99). However, no difference was found in the most recent small, single-institution study that included patients with BSIs. <b>Conclusions</b>: The evidence suggests a potential survival benefit for the BLF strategy over VF in patients with suspected or confirmed BSIs. Larger prospective studies are required to confirm the findings.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-01-27
DOI
https://doi.org/10.3390/jcm15031024
Primary Topic
Antibiotics Pharmacokinetics and Efficacy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effects of the Sequence of Empiric Beta-Lactam and Vancomycin Administration on Clinical Outcomes in Patients with Bloodstream Infection: A Systematic Review

Majed S. Al Yami, Abdulmajeed Alsuwaylihi, Abdulmajeed M. Alshehri
Journal of Clinical Medicine
Antibiotics Pharmacokinetics and Efficacy
article

Effects of the Sequence of Empiric Beta-Lactam and Vancomycin Administration on Clinical Outcomes in Patients with Bloodstream Infection: A Systematic Review

Majed S. Al Yami, Abdulmajeed Alsuwaylihi, Abdulmajeed M. Alshehri
article en

Abstract

<b>Background/Objectives</b>: Beta-lactam antibiotics (BLAs) and vancomycin have remained the cornerstones of therapy for serious bacterial infections, especially bloodstream infections (BSIs). The clinical impact of administering BLAs before vancomycin on outcomes remains unclear and poorly synthesized. Therefore, this systematic review aims to synthesize the available evidence on the impact of the relative timing of BLA administration to vancomycin initiation on important clinical outcomes in patients with BSIs. <b>Methods</b>: A comprehensive search was performed to retrieve clinical studies that evaluated the impact of the sequence of BLA and vancomycin administration on clinical outcomes. Beta-lactam-first group (BLF) included patients who received a BLA before vancomycin, while vancomycin-first group (VF) included patients who received vancomycin prior to BLAs. The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. <b>Results</b>: A total of three retrospective observational studies were included, with a sample size of 29,005 patients, with 24,356 patients in the BLF and 4649 patients in the VF. One study reported that prioritizing BLAs over vancomycin resulted in a 52% reduction in 7-day mortality (adjusted OR, 0.48; 95% CI, 0.33-0.69) and a 55% reduction in 48 h mortality (adjusted OR: 0.45; 95% Cl, 0.24-0.83). Similarly, another study found the BLF strategy was associated with a modest reduction in in-hospital mortality (adjusted OR: 0.89; 95% CI: 0.80-0.99). However, no difference was found in the most recent small, single-institution study that included patients with BSIs. <b>Conclusions</b>: The evidence suggests a potential survival benefit for the BLF strategy over VF in patients with suspected or confirmed BSIs. Larger prospective studies are required to confirm the findings.

Journal of Clinical MedicineVol. 15(3)
King Saud bin Abdulaziz University for Health Sciences (SA), King Abdullah International Medical Research Center (SA), National Guard Health Affairs (SA)
Good health and well-being
Openalex Percentile: Top 75%
Antibiotics Pharmacokinetics and Efficacy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.